Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 12/20 | 0.74 |
| ▸ | PTGS1 | P23219 | 9/20 | 0.74 |
| ▸ | PDPK1 | O15530 | 9/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.60 |
| ▸ | PTGES | O14684 | 1/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.59 |
| ▸ | PDE5A | O76074 | 1/20 | 0.59 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.59 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | CA3 | P07451 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL215932 | 0.86 | PTGS2 (1.00) | PTGS2PTGS1PDPK1CYP2C9PTGES | |
| SCHEMBL6430302 | 0.86 | PTGS2 (1.00) | PTGS2PTGS1PDPK1CYP2C9PTGES | |
| SCHEMBL981158 | 0.85 | PDPK1 (1.00) | PTGS2PTGS1PDPK1CYP2C9PTGES | |
| SCHEMBL7924378 | 0.84 | PTGS2 (0.53) | PTGS2PTGS1PDPK1 | |
| SCHEMBL5923919 | 0.84 | PDPK1 (1.00) | PTGS2PTGS1PDPK1CYP2C9PTGES | |
| SCHEMBL213784 | 0.84 | PTGS2 (1.00) | PTGS2PTGS1PDPK1CYP2C9PTGES | |
| SCHEMBL8111966 | 0.83 | PTGS2 (0.70) | PTGS2PTGS1CA12CA1CA2 | |
| SCHEMBL3306989 | 0.83 | PTGS2 (0.74) | PTGS2PTGS1 | |
| Sulfamide SCHEMBL7143150 | 0.82 | PTGS2 (0.78) | PTGS2PTGS1PDPK1CYP2C9CYP3A4 | |
| SCHEMBL4575824 | 0.82 | PDPK1 (0.90) | PTGS2PTGS1PDPK1CYP2C9PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030220384-A1 | Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia | G.D. SEARLE & CO. (US) | 2003-11-27 | — | — | US | claimed |
| EP-0833664-A1 | COMBINATION OF A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE B 4? RECEPTOR ANTAGONIST FOR THE TREATMENT OF INFLAMMATIONS | G.D. SEARLE & CO. (US) | 1998-04-08 | — | — | EP | claimed |
| WO-1996041645-A1 | COMBINATION OF A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE B4 RECEPTOR ANTAGONIST FOR THE TREATMENT OF INFLAMMATIONS | G.D. SEARLE & CO. (US) | 1996-12-27 | — | — | WO | claimed |
| EP-0833622-B8 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A 5-LIPOXYGENASE INHIBITOR | SEARLE & CO (US) | 2005-10-12 | — | — | EP | disclosed |
| EP-0833622-A1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A 5-LIPOXYGENASE INHIBITOR | G.D. SEARLE & CO. (US) | 1998-04-08 | — | — | EP | disclosed |
| WO-1996041626-A1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A 5-LIPOXYGENASE INHIBITOR | G.D. SEARLE & CO. (US) | 1996-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220384-A1 | Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia | PTGS2, PTGES2, PTGS1 | PTGS2 1/4885PTGS1 3/4885PDPK1 3019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.